News Related to Merck Sharp & Dohme LLC

Related coverage linked through entity extraction aliases.

Breast Cancer Research Advances: New Drug Trials and Resistance Mechanisms Identified

Mar 20, 2026

Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.

Adjuvant Pembrolizumab Maintains Survival Benefit Without Raising New Melanoma Risk in Stage II Disease

Mar 03, 2026

Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.